R
Roel Huis in ‘t Veld
Director, Kriya Materials · Week of September 21, 2026
The small rules arrive first - Compliance, a day job
Nothing happened on PFAS this week. Two smaller things did, and in a small company those are the work.
PFAS first, because everyone asks. ECHA's risk committee gave its opinion in March, the socio-economic committee ran its consultation until 25 May and should adopt its final opinion around the end of this year. Then the Commission, then the member states, then transition periods. My view has not changed: for most uses nothing bites before the end of the decade and the derogation list will be long. Plan with dates, not with fear.
What did happen: on 14 September ECHA clarified what distributors must do for poison-centre notifications under the revised CLP from 1 January 2027. On 18 September the risk committee backed a harmonised classification of resorcinol as an endocrine disruptor (thyroid). Resorcinol sits in some adhesive resins and UV absorbers. Check your raw material list. That is the whole message.
Here is what such a small rule looks like from inside a company our size. We run one hardcoat on two interchangeable acrylate binders from two suppliers, because I want two sources. Chemically they do the same job. One grade has a few percent more of a reaction by-product. That moves the classification from eye irritation to serious eye damage, with a different pictogram. Result: one coating, two safety data sheets, two UFIs, two poison-centre notifications, and a customer asking why the label changed when the coating did not. Our SDS consultant checked the interchangeable-component route in Annex VIII and ruled it out. I would like one SDS per product. The regulation does not care what I would like.
A large coatings company has a regulatory department for this. We have a consultant, a spreadsheet and the habit of reading ECHA's news on Monday. That habit is the point. In fourteen years at Kriya the most useful thing we did on compliance was to make it a design input. Hazard classification sits in the formulation brief next to refractive index and haze. Below three percent of a component and the product avoids serious eye damage; below ten and it avoids skin irritation. A formulator can design to a threshold. A coating without a pictogram is a better product, and the customer's EHS department sees that before purchasing does.
Three habits, none expensive. Keep a live list of every substance in every SDS you issue, with its classification and what ECHA has planned for it; resorcinol went on ours on Friday. Treat a supplier change as a regulatory change: SDS checked before the purchase order, not after the first drum. Tell the customer before the label changes, old and new statements side by side. That costs an hour.
And look at the January 2027 poison-centre change now, not in December. If you sell through distributors, ask them this month who files what. The answers differ per country, as always.
The PFAS restriction will get its headlines. The companies that come through it in good shape are the ones that used the fifty small rules as practice.
Sources
GPC Gateway – EU chemical regulatory news, 14–18 Sept 2026 — https://gpcgateway.com/regulatory-regions/european-union/news/Mw%3D%3D
ECHA Poison Centres – CLP revision and distributors — https://poisoncentres.echa.europa.eu/-/clp-revision-defines-new-role-for-distributors-in-poison-centre-notifications
GPC Gateway – RAC opinion on resorcinol, 18 Sept 2026 — https://gpcgateway.com/news/detail/echa-publishes-rac-opinion-on-resorcinol-endocrine-disruptor-classification/MjY3Mw%3D%3D
White & Case – PFAS restriction timeline (RAC/SEAC) — https://www.whitecase.com/insight-alert/europes-pfas-restriction-proposal-moving-forward